-
Phosbind Acrylamide for TOR Phosphorylation Assays
2026-09-04
Phosbind Acrylamide enables antibody-free visualization of phosphorylation-dependent mobility shifts in proteins linked to TOR signaling. This workflow translates Neurospora nutrient-sensing findings into practical gel-based comparisons while preserving orthogonal controls for localization, complex formation, and phosphatase sensitivity.
-
A 83-01 ALK Inhibitor: Workflow & Applications
2026-09-03
A 83-01 is a selective ALK-5 inhibitor for separating TGF-β-driven transcription, EMT phenotypes, and growth responses from pathway-independent effects. This practical guide connects dose design, organoid and hepatocyte assays, the LPS/TLR4/YAP1 stemness model, and troubleshooting strategies for more interpretable experiments.
-
Poly (I:C): From dsRNA Signal to Translation
2026-09-03
Poly (I:C) is more than a broad immune stimulant: it is a controllable dsRNA signal for interrogating receptor context, interferon biology, mitochondrial ROS, and cell maturation. This thought-leadership article connects plant dsRNA immunity with mammalian translational workflows while outlining practical strategies for using Poly(I:C) with greater mechanistic precision.
-
GSK-923295 and the Logic of Mitotic Precision
2026-09-02
GSK-923295 offers a mechanistically defined way to interrogate CENP-E-dependent chromosome alignment, mitotic arrest, and tumor-cell response. This thought-leadership analysis connects pharmacologic motor inhibition with emerging evidence that CTCF preserves centromere architecture, providing a translational framework for cancer research beyond conventional product-page descriptions.
-
MAPK10-KRT16 Signaling in NSCLC Metastasis
2026-09-02
The reference study identifies a phosphorylation-dependent MAPK10/KRT16/RNF213 pathway that limits non-small cell lung cancer metastasis by promoting KRT16 ubiquitination and proteasomal degradation. Its combination of mechanistic, cellular, animal, and clinical analyses positions MAPK10 expression and KRT16 turnover as testable biomarkers and research targets, while also highlighting important limits on translating kinase perturbation findings into therapy.
-
Hearing Loss, LC–Norepinephrine, and Neurogenesis
2026-09-01
Liu and colleagues identify a causal circuit linking cochlear outer-hair-cell loss to reduced locus coeruleus norepinephrine signaling, impaired adult hippocampal neurogenesis, and cognitive decline in mice. Their rescue experiments show that stimulating PnC VGluT2-to-LC norepinephrine afferents can restore both neurogenic and behavioral outcomes, providing a mechanistic framework for studying hearing-related cognitive vulnerability.
-
ML385: NRF2 Inhibition for Redox and Cancer Research
2026-09-01
ML385 is a selective NRF2 inhibitor for separating antioxidant signaling from ferroptosis, inflammation, and cancer therapeutic resistance. This workflow-oriented guide translates evidence from alcoholic liver disease research into practical assay designs while keeping oncology and cross-domain limitations explicit.
-
Dasatinib Monohydrate in Tumor–Stroma Models
2026-08-31
Dasatinib Monohydrate is examined as a mechanistic probe for patient-derived gastric cancer assembloids, where stromal context can reshape kinase-inhibitor response. This article translates a 2025 assembloid study into a rigorous framework for dose design, pathway readouts, and interpretation beyond conventional CML assays.
-
IRG1–Itaconic Acid Control of TBK1 Signaling
2026-08-31
Chai et al. identify an IRG1–itaconic acid feedback mechanism that limits excessive TBK1-driven type I interferon production by alkylating TBK1 at Cys605 and disrupting its dimerization. The study also introduces ITA-5 and ITA-9 as itaconic acid-based candidate inhibitors, linking infection-associated metabolism with a potential strategy for controlling IFN-I-mediated hyperinflammation.
-
ABT-263 (Navitoclax) in Apoptosis Assays
2026-08-30
ABT-263 (Navitoclax) is a high-affinity BH3 mimetic for dissecting Bcl-2-family control of mitochondrial apoptosis, including resistance mechanisms in colorectal cancer and pediatric leukemia models. This workflow pairs compound handling, apoptosis assay design, mitochondrial priming, and chemoradiotherapy-sensitization experiments for more interpretable results.
-
Eicosapentaenoic Acid: Assay Design Guide
2026-08-29
Eicosapentaenoic Acid (EPA) is more than an omega-3 fatty acid: it is a concentration-sensitive probe for membrane remodeling, endothelial behavior, lipid oxidation, and prostaglandin signaling. This guide translates EPA chemistry and recent PUFA immunology into better assay controls and interpretation.
-
2-Deoxy-D-glucose: Reliable Assay Design
2026-08-28
A scenario-driven guide to using 2-Deoxy-D-glucose, SKU B1027, in viability, proliferation, cytotoxicity, cancer-metabolism, and antiviral studies. It connects concentration selection, readout compatibility, stock handling, cross-domain interpretation, and practical vendor evaluation.
-
Actinomycin D as a Lens on RNA Stability
2026-08-28
Actinomycin D is more than a cytotoxic transcriptional inhibitor: it can expose RNA-decay kinetics within developmental cell-fate networks. This article connects ActD with the PUM-Prdm1-Wnt axis and shows how to interpret transcriptional-stress experiments without confusing mRNA stability with global cell injury.
-
X-Gal Workflows for Cloning and Reporter Assays
2026-08-27
Build more reliable blue-white colony screening and β-galactosidase workflows with practical guidance on stock preparation, plate design, controls, and result validation. The article also explains how cloning-quality decisions can support studies of iRhom2, olfactory receptors, and activity-dependent signaling without overstating what X-Gal can measure.
-
SB-3CT: Mapping MMP9-Driven Matrix Plasticity
2026-08-27
SB-3CT is a selective gelatinase inhibitor for dissecting MMP-2 and MMP-9 activity in extracellular-matrix biology. This article translates recent Adamtsl3–MMP9 findings into concentration-aware assay design spanning tumor metastasis research, perineuronal-net remodeling, and neuroprotection in cerebral ischemia.